PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders

Journal of Inherited Metabolic Disease

Volumn 31, Issue 2, 2008, Pages 217-225

  Djouadi, F ^a   Bastin, J ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE 2; CIPROFIBRATE; CLOFIBRATE; FENOFIBRATE; LONG CHAIN ACYL COENZYME A DEHYDROGENASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR; VERY LONG CHAIN ACYL COENZYME A DEHYDROGENASE; VERY LONG CHAIN FATTY ACID;

AUTOSOMAL RECESSIVE DISORDER; CARBOHYDRATE DIET; CARDIOMYOPATHY; CARNITINE PALMITOYLTRANSFERASE DEFICIENCY; CONCENTRATION RESPONSE; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENERGY METABOLISM; ENZYME ACTIVITY; FATTY ACID OXIDATION; GENE EXPRESSION REGULATION; GENOTYPE PHENOTYPE CORRELATION; HOMOZYGOSITY; HUMAN; HYPOGLYCEMIA; INBORN ERROR OF METABOLISM; LIVER FAILURE; LOW FAT DIET; MISSENSE MUTATION; MITOCHONDRIAL RESPIRATION; MYOPATHY; NEWBORN PERIOD; NONHUMAN; PROTEIN TARGETING; VERY LONG CHAIN ACYL COENZYME A DEHYDROGENASE DEFICIENCY;

ACYL-COA DEHYDROGENASE, LONG-CHAIN; ANIMALS; CARNITINE O-PALMITOYLTRANSFERASE; FATTY ACIDS; HUMANS; LIPID METABOLISM, INBORN ERRORS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MUSCULAR DISEASES; OXIDATION-REDUCTION; PPAR GAMMA;

EID: 43149104941     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-008-0844-7     Document Type: Conference Paper

References (48)

1. U Abshagen S Sporl-Radun J Marinow 1980 Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers Eur J Clin Pharmacol 17 305 308 6995131 10.1007/BF00625805 1:CAS:528:DyaL3cXktlKku7o%3D Abshagen U, Sporl-Radun S, Marinow J (1980) Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers. Eur J Clin Pharmacol 17: 305–308.
2. BS Andresen S Olpin BJ Poorthuis 1999 Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency Am J Hum Genet 64 479 494 9973285 10.1086/302261 1:CAS:528:DyaK1MXhslOltLs%3D Andresen BS, Olpin S, Poorthuis BJ, et al (1999) Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am J Hum Genet 64: 479–494.
3. C Angelini A Federico H Reichmann 2006 Task force guidelines handbook: EFNS guidelines on diagnosis and management of fatty acid mitochondrial disorders Eur J Neurol 13 923 929 16930355 10.1111/j.1468-1331.2006.01482.x 1:STN:280:DC%2BD28rgs1OisA%3D%3D Angelini C, Federico A, Reichmann H, et al (2006) Task force guidelines handbook: EFNS guidelines on diagnosis and management of fatty acid mitochondrial disorders. Eur J Neurol 13: 923–929.
4. T Aoyama JM Peters N Iritani 1998 Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha) J Biol Chem 273 5678 5684 9488698 10.1074/jbc.273.10.5678 1:CAS:528:DyaK1cXhsleis7s%3D Aoyama T, Peters JM, Iritani N, et al (1998) Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem 273: 5678–5684.
5. GD Barish VA Narkar RM Evans 2006 PPAR delta: a dagger in the heart of the metabolic syndrome J Clin Invest 116 590 597 16511591 10.1172/JCI27955 1:CAS:528:DC%2BD28XitlGkt7w%3D Barish GD, Narkar VA, Evans RM (2006) PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 116: 590–597.
6. J Berger DE Moller 2002 The mechanisms of action of PPARs Annu Rev Med 53 409 435 11818483 10.1146/annurev.med.53.082901.104018 1:CAS:528:DC%2BD38Xitl2mt7s%3D Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53: 409–435.
7. JP Bonnefont F Demaugre C Prip-Buus 1999 Carnitine palmitoyltransferase deficiencies Mol Genet Metab 68 424 440 10607472 10.1006/mgme.1999.2938 1:CAS:528:DyaK1MXotVGgs74%3D Bonnefont JP, Demaugre F, Prip-Buus C, et al (1999) Carnitine palmitoyltransferase deficiencies. Mol Genet Metab 68: 424–440.
8. JP Bonnefont F Djouadi C Prip-Buus 2004 Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects Mol Aspects Med 25 495 520 15363638 10.1016/j.mam.2004.06.004 1:CAS:528:DC%2BD2cXnsVyrurk%3D Bonnefont JP, Djouadi F, Prip-Buus C, et al (2004) Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med 25: 495–520.
9. R Cadorniga R Herrero P Pastoriza 1991 Comparative pharmacokinetics of two oral bezafibrate preparations Eur J Drug Metab Pharmacokinet Spec No 3 261 267 Cadorniga R, Herrero R, Pastoriza P, et al (1991) Comparative pharmacokinetics of two oral bezafibrate preparations. Eur J Drug Metab Pharmacokinet Spec No 3: 261–267.
10. Z Cai A Taddei DN Sheppard 2006 Differential sensitivity of the cystic fibrosis (CF)-associated mutants G551D and G1349D to potentiators of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl − channel J Biol Chem 281 1970 1977 16311240 10.1074/jbc.M510576200 1:CAS:528:DC%2BD28XmtlKmtg%3D%3D Cai Z, Taddei A, Sheppard DN (2006) Differential sensitivity of the cystic fibrosis (CF)-associated mutants G551D and G1349D to potentiators of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl − channel. J Biol Chem 281: 1970–1977.
11. TK Chaudhuri S Paul 2006 Protein-misfolding diseases and chaperone-based therapeutic approaches Febs J 273 1331 1349 16689923 10.1111/j.1742-4658.2006.05181.x 1:CAS:528:DC%2BD28XksVWmtLg%3D Chaudhuri TK, Paul S (2006) Protein-misfolding diseases and chaperone-based therapeutic approaches. Febs J 273: 1331–1349.
12. M Deschauer T Wieser S Zierz 2005 Muscle carnitine palmitoyltransferase II deficiency: clinical and molecular genetic features and diagnostic aspects Arch Neurol 62 37 41 15642848 10.1001/archneur.62.1.37 Deschauer M, Wieser T, Zierz S (2005) Muscle carnitine palmitoyltransferase II deficiency: clinical and molecular genetic features and diagnostic aspects. Arch Neurol 62: 37–41.
13. F Djouadi CJ Weinheimer JE Saffitz 1998 A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor alpha-deficient mice J Clin Invest 102 1083 1091 9739042 10.1172/JCI3949 1:CAS:528:DyaK1cXmtFyhsL8%3D Djouadi F, Weinheimer CJ, Saffitz JE, et al (1998) A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor alpha-deficient mice. J Clin Invest 102: 1083–1091.
14. F Djouadi JP Bonnefont L Thuillier 2003 Correction of fatty acid oxidation in Carnitine Palmitoyl Transferase II-deficient cultured skin fibroblasts by bezafibrate Pediatr Res 54 446 451 12840153 10.1203/01.PDR.0000083001.91588.BB 1:CAS:528:DC%2BD3sXntlejs70%3D Djouadi F, Bonnefont JP, Thuillier L, et al (2003) Correction of fatty acid oxidation in Carnitine Palmitoyl Transferase II-deficient cultured skin fibroblasts by bezafibrate. Pediatr Res 54: 446–451.
15. F Djouadi F Aubey D Schlemmer J Bastin 2005a Peroxisome proliferator activated receptor δ (PPARδ) agonist but not PPARα corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells J Clin Endocrinol Metab 90 1791 1797 10.1210/jc.2004-1936 1:CAS:528:DC%2BD2MXisVOhur4%3D Djouadi F, Aubey F, Schlemmer D, Bastin J (2005a) Peroxisome proliferator activated receptor δ (PPARδ) agonist but not PPARα corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells. J Clin Endocrinol Metab 90: 1791–1797.
16. F Djouadi F Aubey D Schlemmer 2005b Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders Hum Mol Genet 14 2695 2703 10.1093/hmg/ddi303 1:CAS:528:DC%2BD2MXpvFeqsr4%3D Djouadi F, Aubey F, Schlemmer D, et al (2005b) Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders. Hum Mol Genet 14: 2695–2703.
17. JN Feige L Gelman L Michalik 2006 From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions Prog Lipid Res 45 120 159 16476485 10.1016/j.plipres.2005.12.002 1:CAS:528:DC%2BD28Xhslyjsrg%3D Feige JN, Gelman L, Michalik L, et al (2006) From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45: 120–159.
18. J Gloerich L Ijlst RJ Wanders 2006 Bezafibrate induces FALDH in human fibroblasts; implications for Sjogren-Larsson syndrome Mol Genet Metab 89 111 115 16837225 10.1016/j.ymgme.2006.05.009 1:CAS:528:DC%2BD28XotlCjsrg%3D Gloerich J, Ijlst L, Wanders RJ, et al (2006) Bezafibrate induces FALDH in human fibroblasts; implications for Sjogren-Larsson syndrome. Mol Genet Metab 89: 111–115.
19. S Gobin-Limballe F Djouadi F Aubey 2007 Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy Am J Hum Genet 81 1133 1143 17999356 10.1086/522375 1:CAS:528:DC%2BD2sXhtl2jurfF Gobin-Limballe S, Djouadi F, Aubey F, et al (2007) Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy. Am J Hum Genet 81: 1133–1143.
20. N Gregersen BS Andresen MJ Corydon 2001 Mutation analysis in mitochondrial fatty acid oxidation defects: exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship Hum Mutat 18 169 189 11524729 10.1002/humu.1174 1:CAS:528:DC%2BD3MXmvFKntLc%3D Gregersen N, Andresen BS, Corydon MJ, et al (2001) Mutation analysis in mitochondrial fatty acid oxidation defects: exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship. Hum Mutat 18: 169–189.
21. T Gulick S Cresci T Caira 1994 The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression Proc Natl Acad Sci U S A 91 11012 11016 7971999 10.1073/pnas.91.23.11012 1:CAS:528:DyaK2MXitV2rsLs%3D Gulick T, Cresci S, Caira T, et al (1994) The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci U S A 91: 11012–11016
22. M Haim M Benderly V Boyko 2006 Decrease in triglyceride level by bezafibrate is related to reduction of recurrent coronary events: a Bezafibrate Infarction Prevention substudy Coron Artery Dis 17 455 461 16845254 10.1097/01.mca.0000224406.60573.8e Haim M, Benderly M, Boyko V, et al (2006) Decrease in triglyceride level by bezafibrate is related to reduction of recurrent coronary events: a Bezafibrate Infarction Prevention substudy. Coron Artery Dis 17: 455–461.
23. PJ Isackson MJ Bennett GD Vladutiu 2006 Identification of 16 new disease-causing mutations in the CPT2 gene resulting in carnitine palmitoyltransferase II deficiency Mol Genet Metab 89 323 331 16996287 10.1016/j.ymgme.2006.08.004 1:CAS:528:DC%2BD28Xht1SgsL%2FK Isackson PJ, Bennett MJ, Vladutiu GD (2006) Identification of 16 new disease-causing mutations in the CPT2 gene resulting in carnitine palmitoyltransferase II deficiency. Mol Genet Metab 89: 323–331.
24. I Issemann S Green 1990 Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 347 645 650 2129546 10.1038/347645a0 1:CAS:528:DyaK3MXhsl2gs7g%3D Issemann I, Green S (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645–650.
25. CH Lee P Olson RM Evans 2003 Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors Endocrinology 144 2201 2207 12746275 10.1210/en.2003-0288 1:CAS:528:DC%2BD3sXktFehtL4%3D Lee CH, Olson P, Evans RM (2003) Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144: 2201–2207.
26. SS Lee T Pineau J Drago 1995 Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators Mol Cell Biol 15 3012 3022 7539101 1:CAS:528:DyaK2MXlslyit70%3D Lee SS, Pineau T, Drago J, et al (1995) Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15: 3012–3022.
27. S Luquet J Lopez-Soriano D Holst 2003 Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability Faseb J 17 2299 2301 14525942 1:CAS:528:DC%2BD3sXpvVSnurY%3D Luquet S, Lopez-Soriano J, Holst D, et al (2003) Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. Faseb J 17: 2299–2301.
28. S Mandard M Muller S Kersten 2004 Peroxisome proliferator-activated receptor alpha target genes Cell Mol Life Sci 61 393 416 14999402 10.1007/s00018-003-3216-3 1:CAS:528:DC%2BD2cXjt1yhurY%3D Mandard S, Muller M, Kersten S (2004) Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci 61: 393–416.
29. T Meade R Zuhrie C Cook 2002 Bezafibrate in men with lower extremity arterial disease: randomised controlled trial Bmj 325 1139 12433762 10.1136/bmj.325.7373.1139 1:CAS:528:DC%2BD38Xps1KitL4%3D Meade T, Zuhrie R, Cook C, et al (2002) Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. Bmj 325: 1139.
30. JP Monk PA Todd 1987 Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia Drugs 33 539 576 3301301 10.2165/00003495-198733060-00002 1:CAS:528:DyaL2sXkvV2jsbg%3D Monk JP, Todd PA (1987) Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs 33: 539–576.
31. SE Olpin 2005 Fatty acid oxidation defects as a cause of neuromyopathic disease in infants and adults Clin Lab 51 289 306 15991803 1:CAS:528:DC%2BD2MXmtFyms7s%3D Olpin SE (2005) Fatty acid oxidation defects as a cause of neuromyopathic disease in infants and adults. Clin Lab 51: 289–306.
32. RK Olsen BS Andresen E Christensen 2003 Clear relationship between ETF/ETFDH genotype and phenotype in patients with multiple acyl-CoA dehydrogenation deficiency Hum Mutat 22 12 23 12815589 10.1002/humu.10226 1:CAS:528:DC%2BD3sXmtVanur4%3D Olsen RK, Andresen BS, Christensen E, et al (2003) Clear relationship between ETF/ETFDH genotype and phenotype in patients with multiple acyl-CoA dehydrogenation deficiency. Hum Mutat 22: 12–23.
33. G Parenti A Zuppaldi M Gabriela Pittis 2007 Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease Mol Ther 15 508 514 17213836 10.1038/sj.mt.6300074 1:CAS:528:DC%2BD2sXhtVKhsr7I Parenti G, Zuppaldi A, Gabriela Pittis M, et al (2007) Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease. Mol Ther 15: 508–514.
34. ER Pearson I Flechtner PR Njolstad 2006 Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations N Engl J Med 355 467 477 16885550 10.1056/NEJMoa061759 1:CAS:528:DC%2BD28XnslyktrY%3D Pearson ER, Flechtner I, Njolstad PR, et al (2006) Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355: 467–477.
35. JM Peters T Aoyama AM Burns 2003 Bezafibrate is a dual ligand for PPARα and PPARβ: studies using null mice Biochim Biophys Acta 1632 80 89 12782154 1:CAS:528:DC%2BD3sXktVyit70%3D Peters JM, Aoyama T, Burns AM, et al (2003) Bezafibrate is a dual ligand for PPARα and PPARβ: studies using null mice. Biochim Biophys Acta 1 632: 80–89.
36. P Rinaldo D Matern MJ Bennett 2002 Fatty acid oxidation disorders Annu Rev Physiol 64 477 502 11826276 10.1146/annurev.physiol.64.082201.154705 1:CAS:528:DC%2BD38XisFGmsb4%3D Rinaldo P, Matern D, Bennett MJ (2002) Fatty acid oxidation disorders. Annu Rev Physiol 64: 477–502.
37. CR Roe L Sweetman DS Roe 2002 Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride J Clin Invest 110 259 269 12122118 1:CAS:528:DC%2BD38XlsVGltr4%3D Roe CR, Sweetman L, Roe DS, et al (2002) Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest 110: 259–269.
38. Saudubray JM, Martin D, de Lonlay P, et al (1999) Recognition and management of fatty acid oxidation defects: a series of 107 patients. J Inherit Metab Dis 22: 488–502.
39. PS Shekhawat D Matern AW Strauss 2005 Fetal fatty acid oxidation disorders, their effect on maternal health and neonatal outcome: impact of expanded newborn screening on their diagnosis and management Pediatr Res 57 78R 86R 15817498 10.1203/01.PDR.0000159631.63843.3E Shekhawat PS, Matern D, Strauss AW (2005) Fetal fatty acid oxidation disorders, their effect on maternal health and neonatal outcome: impact of expanded newborn screening on their diagnosis and management. Pediatr Res 57: 78R–86R.
40. KG Sim J Hammond B Wilcken 2002 Strategies for the diagnosis of mitochondrial fatty acid beta-oxidation disorders Clin Chim Acta 323 37 58 12135806 10.1016/S0009-8981(02)00182-1 1:CAS:528:DC%2BD38Xls1agtbo%3D Sim KG, Hammond J, Wilcken B (2002) Strategies for the diagnosis of mitochondrial fatty acid beta-oxidation disorders. Clin Chim Acta 323: 37–58.
41. JO Solis RH Singh 2002 Management of fatty acid oxidation disorders: a survey of current treatment strategies J Am Diet Assoc 102 1800 1803 12487544 10.1016/S0002-8223(02)90386-X Solis JO, Singh RH (2002) Management of fatty acid oxidation disorders: a survey of current treatment strategies. J Am Diet Assoc 102: 1800–1803.
42. A Tenenbaum M Motro EZ Fisman 2005 Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons Cardiovasc Diabetol 4 14 16168052 10.1186/1475-2840-4-14 Tenenbaum A, Motro M, Fisman EZ (2005) Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 4: 14.
43. L Thuillier H Rostane V Droin 2003 Correlation between genotype, metabolic data, and clinical presentation in carnitine palmitoyltransferase 2 deficiency Hum Mutat 5 493 501 10.1002/humu.10201 Thuillier L, Rostane H, Droin V, et al (2003) Correlation between genotype, metabolic data, and clinical presentation in carnitine palmitoyltransferase 2 deficiency. Hum Mutat 5: 493–501.
44. J Vockley DA Whiteman 2002 Defects of mitochondrial beta-oxidation: a growing group of disorders Neuromuscul Disord 12 235 246 11801395 10.1016/S0960-8966(01)00308-X Vockley J, Whiteman DA (2002) Defects of mitochondrial beta-oxidation: a growing group of disorders. Neuromuscul Disord 12: 235–246.
45. J Vockley RH Singh DA Whiteman 2002 Diagnosis and management of defects of mitochondrial beta-oxidation Curr Opin Clin Nutr Metab Care 5 601 609 12394635 10.1097/00075197-200211000-00002 1:CAS:528:DC%2BD3sXptFek Vockley J, Singh RH, Whiteman DA (2002) Diagnosis and management of defects of mitochondrial beta-oxidation. Curr Opin Clin Nutr Metab Care 5: 601–609.
46. YX Wang CL Zhang RT Yu 2004 Regulation of muscle fiber type and running endurance by PPARdelta PLoS Biol 2 e294 15328533 10.1371/journal.pbio.0020294 Wang YX, Zhang CL, Yu RT, et al (2004) Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2: e294.
47. B Wilcken 2007 Recent advances in newborn screening J Inherit Metab Dis 30 129 133 17342450 10.1007/s10545-007-0538-6 1:STN:280:DC%2BD2s7nt1SjsQ%3D%3D Wilcken B (2007) Recent advances in newborn screening. J Inherit Metab Dis 30: 129–133.
48. B Wilcken V Wiley J Hammond 2003 Screening newborns for inborn errors of metabolism by tandem mass spectrometry N Engl J Med 348 2304 2312 12788994 10.1056/NEJMoa025225 1:CAS:528:DC%2BD3sXkt1KktrY%3D Wilcken B, Wiley V, Hammond J, et al (2003) Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med 348: 2304–2312.